# Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct03014479` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03014479](<https://clinicaltrials.gov/study/NCT03014479>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03014479

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 219 participants.

## Technical summary

Registry record NCT03014479. Randomized; no masking; primary purpose treatment. Start 2017-02-18 (actual); primary completion 2017-10-21 (actual). Results posted on 2019-02-25.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 219 participants (enrolled count; ClinicalTrials.gov record NCT03014479, source copy `cardio:ctgov-nct03014479-2023-12-22`, retrieved 2026-10-26)
- Started: 2017-02-18 (actual) (ClinicalTrials.gov record NCT03014479, source copy `cardio:ctgov-nct03014479-2023-12-22`, retrieved 2026-10-26)
- Primary completion: 2017-10-21 (actual) (ClinicalTrials.gov record NCT03014479, source copy `cardio:ctgov-nct03014479-2023-12-22`, retrieved 2026-10-26)
- Completion: 2017-10-21 (actual) (ClinicalTrials.gov record NCT03014479, source copy `cardio:ctgov-nct03014479-2023-12-22`, retrieved 2026-10-26)
- Results first posted: 2019-02-25 (ClinicalTrials.gov record NCT03014479, source copy `cardio:ctgov-nct03014479-2023-12-22`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT03014479, source copy `cardio:ctgov-nct03014479-2023-12-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03014479-2023-12-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus
- Acronym: TRENDS
- Condition: Type 2 Diabetes
- Intervention (Drug): Trelagliptin
- Intervention (Drug): Daily DPP-4 inhibitor
- Lead sponsor: Takeda
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Takeda (`cardio:org-takeda`)

## Provenance

Content hash: 34cb303a3a1152096556f9db1ef365f78f470591a12e3340cef876262ea07317
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
